SCHEMBL5363476

SCHEMBL5363476

CCN(CC)c1ccc(C=C2C(=O)Nc3ccc(S(=O)(=O)NC)cc32)c(O)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRC P12931 10/20 0.51
NTRK1 P04629 3/20 0.49
SYK P43405 2/20 0.49
NTRK3 Q16288 2/20 0.49
NTRK2 Q16620 2/20 0.49
FCER2 P06734 1/20 0.49
RET P07949 1/20 0.48
CDK2 P24941 2/20 0.47
KDR P35968 6/20 0.47
LCK P06239 5/20 0.47
FYN P06241 5/20 0.47
YES1 P07947 5/20 0.47
FGFR1 P11362 5/20 0.47
PDGFRB P09619 4/20 0.47
AURKA O14965 1/20 0.44
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5358775 0.85 MGAT2 (0.52) SRCSYKRETCA12CA1
SCHEMBL5362182 0.85 RET (0.66) SRCNTRK1SYKNTRK3NTRK2
SCHEMBL5367229 0.85 NTRK1 (0.55) SRCNTRK1SYKNTRK3NTRK2
SCHEMBL5360933 0.83 MAP3K7 (0.58) SRCNTRK1SYKNTRK3NTRK2
SCHEMBL8199426 0.82 SRC (0.59) SRCNTRK1RETKDRPDGFRB
SCHEMBL5374277 0.81 SYK (0.68) SRCNTRK1SYKNTRK3NTRK2
SCHEMBL5364692 0.79 SRC (0.52) SRCNTRK1SYKNTRK3NTRK2
SCHEMBL5369883 0.79 NTRK1 (0.55) SRCNTRK1SYKNTRK3NTRK2
SCHEMBL5361534 0.78 RET (0.49) SRCRETKDR
SCHEMBL7140007 0.78 KDR (0.55) SRCNTRK1SYKNTRK3NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
US-6506763-B2 Useful in prevention and treatment of protein kinase related disorders such as cancer SUGEN, INC. 2003-01-14 US disclosed
EP-0984930-A1 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY Sugen, Inc. (US) 2000-03-15 EP disclosed
WO-1998050356-A1 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY SUGEN, INC. (US) 1998-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK SRC 189/4885NTRK1 223/4885SYK 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.